Clinical trials sponsored by Iovance Biotherapeutics, Inc.

Phase breakdown

Conditions studied

Recruiting trials led by Iovance Biotherapeutics, Inc.

• A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
  NCT05361174 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 11 locations
• A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
  NCT06940739 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 5 locations
• Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
  NCT04614103 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 71 locations
• Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
  NCT05727904 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 81 locations

Common questions

How many trials is Iovance Biotherapeutics, Inc. recruiting for?

Iovance Biotherapeutics, Inc. is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.